Results 181 to 190 of about 1,205,016 (288)

Association between ABO/Rh blood groups and transfusion-transmitted infections among Turkish blood donors: a comprehensive demographic analysis (2015-2021). [PDF]

BMC Infect Dis
Karaca A, Güner ÖR, Günçıkan MN, Yılmaz M, Karadağ GG, Sözmen NN, Sağdur L, Kınık K, Yılmaz FM.   +8 more
europepmc   +1 more source

Seroprevalence of Transfusion-Transmitted Infections among Voluntary and Replacement Blood Donors at the Peshawar Regional Blood Centre, Khyber Pakhtunkhwa, Pakistan. [PDF]

J Lab Physicians, 2021
Saba N, Nasir JA, Waheed U, Aslam S, Mohammad I, Wazeer A, Ahmed S, Nisar M.   +7 more
europepmc   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Seroprevalence of transfusion transmitted infections among blood donors in Hargeisa, Somaliland: a retrospective study. [PDF]

BMC Public Health
Farah AI, Abdi HM, Mohmed AJ, Abase SM, Ismail MM, Qalib JM, Johannessen A, Orlien SMS.   +7 more
europepmc   +1 more source

Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies

British Journal of Haematology, EarlyView.
Gene therapy is revolutionizing treatment paradigms for haemoglobinopathies, establishing a translational framework for disorders that impact red blood cell development. In their paper, Joshi et al. describe the preclinical and early clinical landscape of gene therapies for non‐haemoglobinopathy erythroid disorders and highlight common thematic ...
Gaurav Joshi, Nandakumar Natarajan, Kathryn E. Dickerson, Richard A. Voit   +3 more
wiley   +1 more source

The Frequency of Transfusion-Transmitted Infections in Healthy Blood Donors at King Abdulaziz Hospital, Makkah, Kingdom of Saudi Arabia. [PDF]

Medicina (Kaunas)
Halawani SH, Aldosari MS, Al-Zahrani FS, Bulushi MA, Moamenah RS, Algufairy SF, Bajuaifer N, Allohibi YA, Zaghloul A.   +8 more
europepmc   +1 more source

Prevalence and predictors of transfusion-transmitted infections among blood donor types at a teaching hospital in Ghana: Implications for haemovigilance. [PDF]

PLoS One
Charwudzi A, Adela EM, Pereko KKA, Ampofo M, Fenuku A, Azumah DE, Asemah AR, Ahiakwah E, Osei AA, Edzie EKM.   +9 more
europepmc   +1 more source

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era

British Journal of Haematology, EarlyView.
Summary Data on real‐world survival and treatment patterns in large, unselected myelofibrosis (MF) cohorts remain limited. We analysed 1649 patients with MF diagnosed from 2010 onwards and included in the Spanish Myelofibrosis Registry across 64 centres. Janus kinase (JAK) inhibitors were administered to approximately half of the patients.
Juan‐Carlos Hernández‐Boluda, Eduardo Arellano‐Rodrigo, Manuel Pérez‐Encinas, José‐María Raya, María‐Teresa Gómez‐Casares, Francisca Ferrer‐Marín, Alberto Hernández‐Sánchez, María‐Laura Fox, Anna Angona, Beatriz Cuevas, María‐Isabel Mata‐Vázquez, Rosa Ayala, Natalia de las Heras, Elvira Mora, Valentín García‐Gutiérrez, Alicia Senín, Jasson Villarreal, Blanca Xicoy, Raúl Pérez‐López, María García‐Fortes, Sonia González de Villambrosia, Elena Magro, María‐José Ramírez, Paula Gómez, Angel Ramírez‐Payer, Clara Martínez‐Valverde, Lucía Pérez‐Lamas, Carmen García‐Hernández, Mercedes Gasior, Luis‐Miguel Juárez‐Salcedo, Francisco Ibáñez, María‐Luisa Antelo, Lucía Guerrero, Alberto Alvarez‐Larrán, Arturo Pereira, on behalf of the Spanish MPN Group (GEMFIN)   +35 more
wiley   +1 more source

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukaemia patients: A multicentre real‐world study

British Journal of Haematology, EarlyView.
Summary Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS‐like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second‐generation FLT3 inhibitor gilteritinib provides better disease control compared to standard relapse therapies and was approved based on two ...
Desiree Kunadt, Sven Zukunft, Christoph Röllig, Stephan Metzelder, Andreas Burchert, Eva Wagner‐Drouet, Oliver Kriege, Christoph Schliemann, Matthias Stelljes, Julian Ronnacker, Wolfgang Bethge, Jan Frederic Weller, Björn Steffen, Gesine Bug, Khouloud Kouidri, Claudia Baldus, Lars Fransecky, Elisa Sala, Uwe Platzbecker, Klaus Metzeler, Sabine Kayser, Inken Hilgendorf, Andreas Hochhaus, Tim H. Brümmendorf, Edgar Jost, Anna Dorottya Doleschall, Thomas Schroeder, Jennifer Kaivers, Lambros Kordelas, Udo Holtick, Julia M. Unglaub, Tim Sauer, Paul Sebastian Jäger, Guido Kobbe, Elena Stauffer, Johanna Tischer, Tobias Herold, Normann Steiner, David Nachbaur, Nicolaus Kröger, Jochen J. Frietsch, Sabrina Kraus, Hermann Einsele, Mathias Hänel, Judith Schaffrath, William Krüger, Anne Brandenburg, Tobias A. W. Holderried, Laura Reinhardt, Markus Maulhardt, Christian Thiede, Martin Bornhäuser, Johannes Schetelig, Jan M. Middeke, Friedrich Stölzel, for the German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL)   +55 more
wiley   +1 more source

Association of ABO and Rhesus Blood Types with Transfusion-Transmitted Infections (TTIs) Among Apparently Healthy Blood Donors at Bahir Dar Blood Bank, Bahir Dar, North West, Ethiopia: A Retrospective Cross-Sectional Study. [PDF]

J Blood Med, 2022
Legese B, Shiferaw M, Tamir W, Eyayu T, Damtie S, Berhan A, Getie B, Abebaw A, Solomon Y.   +8 more
europepmc   +1 more source